A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
BeiGene
BeiGene
Sichuan Cancer Hospital and Research Institute
BeiGene
CStone Pharmaceuticals
Innovent Biologics (Suzhou) Co. Ltd.
Radiation Therapy Oncology Group
Sun Yat-sen University
Fudan University
Chinese University of Hong Kong
The First Affiliated Hospital of Henan University of Science and Technology
Swiss Cancer Institute
Federation Francophone de Cancerologie Digestive
Sichuan Cancer Hospital and Research Institute
Fudan University
Alliance for Clinical Trials in Oncology
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
University of Oxford